Ezetimibe; Rosuvastatin Calcium Patent Expiration
Ezetimibe; Rosuvastatin Calcium is Used for lowering high levels of lipids in the blood. It was first introduced by Althera Pharmaceuticals Llc
Ezetimibe; Rosuvastatin Calcium Patents
Given below is the list of patents protecting Ezetimibe; Rosuvastatin Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Roszet | US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | May 01, 2033 | Althera Pharms |
| Roszet | US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | May 01, 2033 | Althera Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ezetimibe; Rosuvastatin Calcium's patents.
Latest Legal Activities on Ezetimibe; Rosuvastatin Calcium's Patents
Given below is the list recent legal activities going on the following patents of Ezetimibe; Rosuvastatin Calcium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Feb, 2023 | US10376470 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Oct, 2021 | US9763885 |
| Email Notification Critical | 08 Oct, 2021 | US9763885 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Oct, 2021 | US10376470 |
| Email Notification Critical | 08 Oct, 2021 | US10376470 |
| Correspondence Address Change Critical | 06 Oct, 2021 | US10376470 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Nov, 2020 | US9763885 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Aug, 2019 | US10376470 |
| Recordation of Patent Grant Mailed Critical | 13 Aug, 2019 | US10376470 |
| Email Notification Critical | 25 Jul, 2019 | US10376470 |
Ezetimibe; Rosuvastatin Calcium's Family Patents
